Capricor Therapeutics, Inc. Stock News

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Capricor Therapeutics maintains a "Hold" rating despite positive phase 3 HOPE-3 results for Deramiocel in DMD cardiomyopathy. HOPE-3 met both primary [PUL v2.0] and key secondary [LVEF] endpoints, aligning with FDA's requirements for potential BLA resubmission of Deramiocel. Regulatory uncertainty remains, particularly regarding CMC issues and whether or not HOPE-3 fully satisfies FDA approval ...

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares...

Capricor stock skyrocketed to an eight-year high Wednesday on positive results for its Duchenne muscular dystrophy treatment.

Capricor Therapeutics Inc (NASDAQ:CAPR) is one of the best stocks on Wall Street today, up 263% to trade at $23.09, after the biotech company's cell therapy for a heart condition related to Duchenne's muscular dystrophy met the ‌main goal of a late-stage study.

Capricor Therapeutics said on Wednesday its cell therapy for a heart condition related to a rare muscular disorder met the main goal of a late-stage study, months after U.S. regulators rejected its initial approval bid.

Capricor Therapeutics, Inc. ( CAPR ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LL...